RESPeRATE Expands Distribution At Rite Aid
New York, N.Y. (PRWEB) December 14, 2009
InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), announced today that RESPeRATE®, the world’s first FDA-cleared, over-the-counter blood pressure treatment device, is now available at 500 Rite Aid stores in the New York metropolitan area, including stores in Long Island, New Jersey and Connecticut. The expansion comes after a successful pilot at over 800 Rite Aid stores on the West Coast.
With this expansion, RESPeRATE will be available on both coasts at a total of 1,300 Rite Aid. Until now, RESPeRATE has served the important New York metro area through select independent pharmacies. The New York Metro expansion with Rite Aid follows the Company’s announced national distribution in the UK with Boots UK Limited, the largest pharmacy chain in the UK.
“In both the UK and US markets, leading pharmacy chains are moving from pilot phase to expansion phase after realizing that there is significant demand for RESPeRATE” said Erez Gavish, President and CEO of InterCure. “In the US, we are taking a disciplined approach to expansion, targeting key markets on both the West and East Coasts. In the NY metro region, our successful track record with independent pharmacies, base of local supportive physicians and broad marketing exposure gives us confidence that we will continue to be successful.”
RESPeRATE® is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically-proven to lower blood pressure through paced breathing therapy. The device uses the body’s natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a “therapeutic zone” of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.
About InterCure Ltd. and RESPeRATE
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $ 42 billion hypertension industry with the world’s first FDA-cleared, OTC blood pressure treatment device, RESPeRATE® (http://www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective adjunctive non-drug therapy with no side effects.
RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device’s efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.
With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world’s most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.
InterCure has an exciting product pipeline based on its broadly-patented “Device-Guided Breathing” technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.
Forward-Looking Statements
This news release may contain forward-looking statements that are based on the Company’s current beliefs and assumptions and on information currently available to its management and the Company assumes no obligation to update these forward-looking statements publicly. As forward-looking statements involve known and unknown risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release.
Contact:
Brian Packard
InterCure, Inc.
+1-646-652-5800 x.7134
###
©Copyright 1997-
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
